Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14624782 | 0.87 | TSHR (0.36) | ALOX15PKMTHRBHTTKDM4E | |
| SCHEMBL14634538 | 0.85 | PKM (0.36) | PKMTHRBHTTKDM4EMEN1 | |
| SCHEMBL3763202 | 0.84 | ALOX15 (0.38) | ALOX15LMNA | |
| SCHEMBL1734711 | 0.81 | ALOX15 (0.37) | ALOX15KDM4EMEN1KMT2AATM | |
| SCHEMBL12746064 | 0.77 | ALOX15 (0.40) | ALOX15 | |
| SCHEMBL13059661 | 0.76 | CYP4F2 (0.38) | PKMTHRBHTTKDM4EMEN1 | |
| SCHEMBL6434714 | 0.74 | ALOX15 (0.43) | ALOX15KDM4EMEN1KMT2AATM | |
| Triethyl Citrate SCHEMBL21518137 | 0.74 | GAA (0.43) | PKMTHRBHTTKDM4EMEN1 | |
| SCHEMBL4942630 | 0.74 | PKM (0.40) | PKMTHRBHTTKDM4EMEN1 | |
| SCHEMBL14634208 | 0.73 | GAA (0.38) | PKMTHRBHTTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018019549-A1 | DIOXOLANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF HOMOHARRINGTONINE | INDENA S.P.A. (IT) | 2018-02-01 | — | — | WO | disclosed |
| EP-3275875-A1 | DIOXOLANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF HOMOHARRINGTONINE | INDENA S.p.A. (IT) | 2018-01-31 | — | — | EP | disclosed |
| US-RE45128-E1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2014-09-09 | — | — | US | disclosed |
| US-RE45128-E1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2014-09-09 | — | — | US | disclosed |
| EP-1907371-B1 | PROCESS FOR PREPARING 2-METHOXYCARBONYLMETHYL-6,6-DIMETHYL-2- TETRAHYDROPYRAN CARBOXYLIC ACID | ERREGIERRE SPA (IT) | 2011-11-23 | — | — | EP | disclosed |
| US-8008514-B2 | Process for preparing 2-methoxycarbonylmethyl-6,6-dimethyl-2-tetrahydropyran carboxylic acid | ERREGIERRE S.P.A. (IT) | 2011-08-30 | — | — | US | disclosed |
| US-8008514-B2 | Process for preparing 2-methoxycarbonylmethyl-6,6-dimethyl-2-tetrahydropyran carboxylic acid | ERREGIERRE S.P.A. (IT) | 2011-08-30 | — | — | US | disclosed |
| CN-101233123-B | Process for the preparation of 2-methoxycarbonylmethyl-6, 6-dimethyl-2-tetrahydropyran carboxylic acid | ERREGIERRE SPA | 2011-05-11 | — | — | CN | disclosed |
| US-7842687-B2 | Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration | CHEMGENEX PHARMACEUTICALS, INC. (AU) | 2010-11-30 | — | — | US | disclosed |
| US-7842687-B2 | Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration | CHEMGENEX PHARMACEUTICALS, INC. (AU) | 2010-11-30 | — | — | US | disclosed |
| US-7169774-B2 | Cephalotaxane derivatives and their processes of preparation and purification | STRAGEN PHARMA S.A. (CH) | 2007-01-30 | — | — | US | disclosed |
| US-7169774-B2 | Cephalotaxane derivatives and their processes of preparation and purification | STRAGEN PHARMA S.A. (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2005-04-28 | — | — | US | disclosed |
| EP-1064285-B1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | STRAGEN PHARMA SA (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-6831180-B1 | Substituted tertiary carboxylic oxacycloalkane acids, used to prepare anhydro-homo-harringtonic acids by semi-synthesis; hydroxyl function of a cephalotaxane is esterified with a 2-carboxyl-2-alkyl-1-oxacycloalkane claimed intermediate; (indexing from 7169774 added) | STRAGEN PHARMA SA. (CH) | 2004-12-14 | — | — | US | disclosed |
| US-6613900-B2 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | ONCOPHARM CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-20020045750-A1 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | IVAX International GmbH (CH) | 2002-04-18 | — | — | US | disclosed |
| EP-1064285-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Oncopharm Corporation (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999048894-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | ONCOPHARM CORPORATION (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | ALOX15 1186/4885PKM 3591/4885THRB 1874/4885 |
| US-20020045750-A1 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | AAAS, AARS1, AADAT | ALOX15 722/4885PKM 3448/4885THRB 2615/4885 |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | ALOX15 1186/4885PKM 3591/4885THRB 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.